Atopic Dermatitis (AD)

Omalizumab Therapeutic Cheat Sheet
Omalizumab
by Alexis Carrington, MD on
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr …

Continue reading "Omalizumab Therapeutic Cheat Sheet"

Skincare Mondays | Improving Quality of Life for Eczema Patients
eczema
by Johnson & Johnson Consumer Health on
Atopic dermatitis (AD) is a chronic skin condition characterized by pruritus, inflammation, and acute flare-ups of eczematous lesions over dry skin.1 The wide range of clinical manifestations, the visible nature of the disease, and the intense itching significantly affects patients’ quality of life.2  Up to 80% of children with AD experience sleep disturbances.3 Sixty-seven percent of children …

Continue reading "Skincare Mondays | Improving Quality of Life for Eczema Patients"

Atopic Dermatitis (AD) Treatment Initiation and Monitoring
atopic dermatitis (AD)
by Mojgan Hosseinipour, DO, FAAD on
During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.  CASE 1 51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA …

Continue reading "Atopic Dermatitis (AD) Treatment Initiation and Monitoring"